Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Phesgo 1200mg/600mg Injection
Manufacturer/Marketed By : ROCHE PRODUCTS INDIA PVT LTD
$5252.55 $4402.50
Phesgo 1200mg/600mg Injection is a targeted therapy containing the active constituents pertuzumab and trasrtuzumab. It is used to treat a type of breast cancer (human epidermal growth factor receptor 2...
PERTUZUMAB,TRASTUZUMAB
Active Pharmaceutical Ingredient
Phesgo 1200mg/600mg Injection
$5,252.55
$4,402.50
Phesgo 1200mg/600mg Injection is a targeted therapy containing the active constituents pertuzumab and trasrtuzumab. It is used to treat a type of breast cancer (human epidermal growth factor receptor 2 positive breast cancer) that has spread to other parts of the body (metastasized) or cancer that has come back after the treatment. It will also be given before or after the surgery if the cancer has not metastasized. Cancer occurs when cells begin to grow abnormally in an uncontrolled manner. Before taking Phesgo 1200mg/600mg Injection, talk to the physician if you have heart problems, have had radiotherapy, or have allergic conditions. This medication is not recommended for adolescents and children under 18. In patients with early-stage HER2-positive breast cancer, adding pertuzumab or trastuzumab to standard chemotherapy can reduce the risk of recurrence and improve disease-free survival.
Active Pharmaceutical Ingredient
Uses
• Early breast cancer
• Metastatic breast cancer
Benefits
Phesgo (pertuzumab and trastuzumab) 1200mg/600mg injection is a fixed-dose combination therapy used for HER2-positive breast cancer, offering the therapeutic benefits of both monoclonal antibodies in a convenient subcutaneous formulation. Pertuzumab prevents HER2 receptor dimerization, while trastuzumab blocks HER2 signalling and triggers immune-mediated tumour cell destruction, collectively inhibiting cancer cell growth and proliferation. By targeting HER2-positive cells, Phesgo reduces tumour progression, improves survival rates, and enhances treatment convenience compared to intravenous administration.
Side Effects
Side effects are unwanted symptoms caused by medicines. Even though all medicines cause side effects, not everyone gets them. The Phesgo Injection side effects are:
Most Common Side Effects
• Febrile neutropenia (fever with low white blood cell count)
• Neutropenic sepsis (a severe infection due to low white blood cell count)
• Decreased ejection fraction (a measure of heart function)
• Cardiac failure
• Pneumonitis/pulmonary fibrosis (lung inflammation or scarring)
• Hypersensitivity reactions, including anaphylaxis
• Severe injection-related reactions
Common Side Effects
• Alopecia (hair loss)
• Nausea
• Diarrhea
• Anemia
• Asthenia (weakness)
• Fatigue
• Stomatitis (inflammation of the mouth)
• Myalgia (muscle pain)
• Arthralgia (joint pain)
• Constipation
• Neutropenia (low white blood cell count)
• Vomiting
• Radiation skin injury
• Dysgeusia (altered taste)
• Headache
• Decreased appetite
• Insomnia
• Peripheral sensory neuropathy
• Rash
• Dry skin
• Mucosal inflammation
• Injection site reactions (e.g., pain, redness)
• Cough
How To Use
Phesgo 1200mg/600mg Injection is administered subcutaneously, not intravenously. The initial loading dose of 1,200 mg pertuzumab and 600 mg trastuzumab is given over approximately 8 minutes, followed every three weeks by a maintenance dose of 600 mg pertuzumab and 600 mg trastuzumab administered over approximately 5 minutes. Injections should alternate between the left and right thighs, ensuring each new injection is at least 2.5 cm away from the previous site and avoiding areas that are red, bruised, tender, or hard. Do not split the dose between multiple syringes or injection sites. After administering the loading dose, observe the patient for 30 minutes; for maintenance doses, a 15-minute observation period is recommended to monitor for injection-related reactions. If a serious hypersensitivity reaction occurs, discontinue the injection immediately and permanently.
Safety Advice
• Breast Feeding: It is unknown whether the Phesgo 600 Injection is excreted in human milk. So breastfeeding women should consult their doctor before taking it.
• Alcohol: Alcohol use can negatively affect the immune system, and patients receiving Phesgo 1200mg/600mg Injection may already have compromised immune systems due to their medical condition or treatment. Therefore, it is generally recommended that patients limit their alcohol consumption or avoid alcohol entirely while receiving it.
• Liver: Patients with pre-existing liver disease or impaired liver function may be at increased risk for the potential side effects of Injection Phesgo, including liver toxicity. So patients should discuss it with their healthcare provider before taking it.
• Lungs: Phesgo 1200mg/600mg Injection can cause side effects, and the safety of their use in the lungs depends on several factors. Patients should consult their doctor if they have any pre-existing health condition before taking this medication.
• Driving: Patients should always monitor their response to the Phesgo 1200mg/600mg Injection medication and be cautious when driving or operating machinery if they experience any side effects that may impair their ability to do so safely.
• Pregnancy: Phesgo 1200mg/600mg Injection may harm the developing fetus, so it is unsafe to use during pregnancy.
Disclaimer
Sidmex Inovia strives to provide accurate and reliable information; however, all content on this website, including product descriptions and compositions, is for informational purposes only and should not be considered a substitute for professional medical advice, diagnosis, or treatment.
Users are advised to consult a qualified healthcare professional before making any medical decisions. The information provided should not be used for self-diagnosis or self-medication.
All products listed are intended strictly for B2B and bulk inquiry purposes only. Sidmex Inovia does not promote direct consumer use and aims to support, not replace, the healthcare professional–patient relationship.
Product names, trademarks, and brands belong to their respective owners, and their use does not imply any affiliation or endorsement. Sidmex Inovia shall not be held responsible for any consequences arising from the use of the information provided on this website.